CoChat

RNA-targeting and gene editing therapies for transthyretin amyloidosis

Open access
Aimo, Alberto, Castiglione, Vincenzo, Rapezzi, Claudio, Franzini, Maria, Panichella, Giorgia, Vergaro, Giuseppe, Gillmore, Julian, Fontana, Marianna, Passino, Claudio, Emdin, Michele · 2022 · Nature Reviews Cardiology
Cited by 163

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Transthyretin (TTR) is a tetrameric protein synthesized mostly by the liver and secreted into the plasma. TTR molecules can misfold and form amyloid fibrils in the heart and peripheral nerves, either as a result of gene variants in TTR or as an ageing-related phenomenon, which can lead to amyloid TTR (ATTR) amyloidosis. Some of the proposed strategies to treat ATTR amyloidosis include blocking TTR synthesis in the liver, stabilizing TTR tetramers or disrupting TTR fibrils. Small interfering RNA (siRNA) or antisense oligonucleotide (ASO) technologies have been shown to be highly effective for the blockade of TTR expression in the liver in humans. The siRNA patisiran and the ASO inotersen have been approved for the treatment of patients with ATTR variant polyneuropathy, regardless of the presence and severity of ATTR cardiomyopathy. Preliminary data show that therapy with patisiran improves the cardiac phenotype rather than only inducing disease stabilization in patients with ATTR variant polyneuropathy and concomitant ATTR cardiomyopathy, and this drug is being evaluated in a phase III clinical trial in patients with ATTR cardiomyopathy. Furthermore, ongoing phase III clinical trials will evaluate another siRNA, vutrisiran, and a novel ASO formulation, eplontersen, in patients with ATTR variant polyneuropathy or ATTR cardiomyopathy. In this Review, we discuss these approaches for TTR silencing in the treatment of ATTR amyloidosis as well as the latest strategy of genome editing with CRISPR–Cas9 to reduce TTR gene expression. Transthyretin amyloidosis is a progressive, life-threatening disease caused by the accumulation of misfolded transthyretin, predominantly in the nerves and heart. In this Review, Aimo and colleagues provide an update on the treatment strategies aimed at blocking transthyretin production, including small interfering RNAs, antisense oligonucleotides and gene editing approaches. Transthyretin (TTR) is a tetrametric protein synthesized mainly by the liver that can misfold and deposit as amyloid fibrils, predominantly in peripheral nerves and the heart, which can result in amyloid TTR (ATTR) amyloidosis. Therapeutic options for ATTR amyloidosis include pharmacological agents that inhibit hepatic synthesis of TTR, stabilize the tetramer or disrupt the amyloid fibrils. The small interfering RNA (siRNA) patisiran and the antisense oligonucleotide (ASO) inotersen block liver TTR expression and have been approved for the treatment of variant ATTR polyneuropathy (ATTRv-PN). Phase III trials are ongoing on patisiran for the treatment of ATTR cardiomyopathy (ATTR-CM) and the siRNA vutrisiran for hereditary ATTRv-PN or ATTR-CM. A novel ASO formulation, eplontersen, is being evaluated in phase III trials in patients with ATTRv-PN or ATTR-CM. A genome editing strategy using CRISPR–Cas9 to silence the TTR gene is being investigated in a phase I trial. Transthyretin (TTR) is a tetrametric protein synthesized mainly by the liver that can misfold and deposit as amyloid fibrils, predominantly in peripheral nerves and the heart, which can result in amyloid TTR (ATTR) amyloidosis. Therapeutic options for ATTR amyloidosis include pharmacological agents that inhibit hepatic synthesis of TTR, stabilize the tetramer or disrupt the amyloid fibrils. The small interfering RNA (siRNA) patisiran and the antisense oligonucleotide (ASO) inotersen block liver TTR expression and have been approved for the treatment of variant ATTR polyneuropathy (ATTRv-PN). Phase III trials are ongoing on patisiran for the treatment of ATTR cardiomyopathy (ATTR-CM) and the siRNA vutrisiran for hereditary ATTRv-PN or ATTR-CM. A novel ASO formulation, eplontersen, is being evaluated in phase III trials in patients with ATTRv-PN or ATTR-CM. A genome editing strategy using CRISPR–Cas9 to silence the TTR gene is being investigated in a phase I trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41569-022-00683-z

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 163

Metadata

Authors
Aimo, A., Castiglione, V., Rapezzi, C., Franzini, M., Panichella, G., Vergaro, G., Gillmore, J., Fontana, M., Passino, C., & Emdin, M.
Venue
Nature Reviews Cardiology
Published
2022-03-23
Volume
19
Issue
10
Pages
655-667
ISSN
  • 1759-5002 (ISSN-L)
  • 1759-5010
OpenAlex
W4220826461
Cited by
163
References
17
FWCI
2.99
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RNA-targeting and gene editing therapies for transthyretin amyloidosis. https://app.cochat.ai/papers/10.1038/s41569-022-00683-z
The paper
Aimo, A., Castiglione, V., Rapezzi, C., Franzini, M., Panichella, G., Vergaro, G., Gillmore, J., Fontana, M., Passino, C., & Emdin, M. (2022). RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nature Reviews Cardiology. https://doi.org/10.1038/s41569-022-00683-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.